Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Abbott lowers 2002 guidance

ABT lowered its EPS guidance for the second quarter to $0.51 from $0.53 and full year

Read the full 164 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE